Madridge Journal of Internal and Emergency Medicine

ISSN: 2638-1621

International Translational and Regenerative Medicine Conference
April 25-27, 2018 | Rome, Italy

Fingolimod (FTY720) as an Anti-Multiple Sclerosis Oral Ultimate Therapy

Sara T Alrashood1, Fadilah S Aleanizy2, FulwahAlqahtani2, AhadAbushal3, Noor AlSalama3 and Ghada S Hassan4

1Department of Pharmaceutical Chemistry, King Saud University, Saudi Arabia
2Department of Pharmaceutics, King Saud University, Saudi Arabia
3College of Pharmacy, King Saud University, Saudi Arabia
4Department of Medicinal Chemistry, Mansoura University, Egypt

DOI: 10.18689/2638-1621.a1.002

Download PDF

Multiple Sclerosis (MS) is a chronic progressive autoimmune disease. It has complex symptoms and challenges. Patients suffer the most from the inconvenience and intolerability till the old injectable disease modifying therapies. Therefore our research is highlighting the scoop on the newly available treatment using the oral therapies proceeding from their chemical nature and structure to prove their superiority to the traditional ones in controlling MS progression. This can lead to an improvement inlife quality for MS patients with the enhanced tolerability for oral drugs that is best achieved by using Fingolimod that is considered as the first approved oral drug for this disease.